
    
      The subjects with office SBP of 140-180 mmHg with 3 antihypertensive medications of different
      classes including thiazide or thiazide-like diuretics and daytime average daytime SBP of â‰¥
      135 mmHg are enrolled in the 4-week run-in period. During run-in period, subjects will
      receive sevikar HCT (5/20/12.5 mg). After a 4-week run-in period, subjects who have
      uncontrolled average home SBP, defined as average of >135 mmHg, will be randomized to either
      spironolactone or amiloride. 118 subjects will be randomly assigned to one of the two
      treatment groups. Subjects randomly assigned to one of the two treatment groups will receive
      12.5 mg of spironolactone and the other group will receive 5 mg of amiloride. Subjects who
      did not reach the target blood pressure after 4 weeks of treatment should be increased to 25
      mg of spironolactone or 10 mg of amiloride. After 12 weeks of treatment, study will be end.
    
  